Oct 29, 2009 | Drugs.com
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense ...
Oct 29, 2009 - Genta Incorporated today announced top-line results from AGENDA, the Company's Phase 3 trial of Genasense Injection in patients with advanced melanoma.
Genta Incorporated Announces Second Quarter 2009 Financial Results
Genta Incorporated today announced financial results for the quarter ended June 30, 2009.
New Publication Confirms Critical Link of LDH Biomarker in Genasense...
BERKELEY HEIGHTS, NJ July 14, 2009 Genta Incorporated announced publication of a paper that independently confirms the link of a key biomarker to overall survival in patients with advanced melanoma.
Genasense Combined with Temodar and Abraxane Shows Preliminary...
Jun 3, 2009 - Genta Incorporated announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Company's lead oncology product, Genasense Injection, in a chemotherapy program for patients with advanced melanoma.
Also on Topix